Fever after cytotoxic therapy of chronic lymphocytic leukemia.
Zingman
B S
BS
Division of Infectious Diseases, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001398:Aztreonam / Q000627:therapeutic use; D002177:Candidiasis / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D005334:Fever / Q000139:chemically induced* / Q000188:drug therapy; D006020:Glycopeptides; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D008997:Monobactams / Q000627:therapeutic use; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D006020:Glycopeptides; D008997:Monobactams; D008795:Metronidazole; D014740:Vidarabine; D001398:Aztreonam; C024352:fludarabine